Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D8-MMAF is a microtubule destroyer, deuterated form of MMAF.
产品描述 | D8-MMAF is a microtubule destroyer, deuterated form of MMAF. |
体外活性 | MMAF showed cytotoxicity in vitro against a group of cell lines. Karpas 299, H3396, 786-O and Caki-1 have IC50 values of 119, 105, 257 and 200 nM, respectively. Targeted MMAF is more effective than free drug, and the cAC10 conjugate of MMAF shows significant activity. On a molar basis, the average potency of cAC10-L1-MMAF4 is more than 2200 times higher than free MMAF, and it is active in all tested CD30 positive cell lines. |
体内活性 | The maximum tolerated dose of MMAF (> 16 mg / kg) mice is much higher than that of MMAE (1 mg / kg). The MTD of cAC10-L1-MMAF4 is 50 mg / kg in mice and 15 mg / kg in rats. The corresponding cAC10-L4-MMAF4 ADC is much less toxic, with MTD greater than 150 mg / kg and 90 mg / kg in mice and rats, respectively. |
别名 | Monomethylauristatin F D8 |
分子量 | 740.01 |
分子式 | C39H57D8N5O8 |
CAS No. | T10949 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
D8-MMAF T10949 Others D8 MMAF Monomethylauristatin F D8 D8MMAF D-8-MMAF Inhibitor inhibitor inhibit